Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

The stocks on this list are not high-flying tech names, shoot-for-the-moon startups, or even high-growth names, but they are ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

Discover why ACM trades at a discount, its global expansion efforts, and potential 119% upside. Learn how partnerships fuel ...

Most growth stocks have struggled in early 2025. Despite this volatility, several innovators continue to post strong ...